Table 2.
SSTR2A | p | HIF-2αNUC | p | |||
---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | |||
(n = 21) | (n = 24) | (n = 14) | (n = 31) | |||
Age at Initial Diagnosis
(median, range) |
40 (17–70) | 59 (18–80) | 0.005 | 41 (17–70) | 50 (18–80) | 0.333 |
Sex | ||||||
Female | 15 | 13 | 0.356 | 7 | 21 | 0.326 |
Male | 6 | 11 | 7 | 10 | ||
Primary Tumor Location | ||||||
Adrenal | 7 | 11 | 0.599 | 0 | 18 | <0.001 |
Extra-adrenal | 14 | 13 | 14 | 13 | ||
Abdominal | 10 | 10 | 11 | 9 | ||
Head and neck | 2 | 0 | 1 | 1 | ||
Bladder | 2 | 3 | 2 | 3 | ||
Tumor Site | ||||||
Adrenal | 7 | 10 | 0.704 | 0 | 17 | 0.001 |
Abdominal | 10 | 9 | 10 | 9 | ||
Liver | 0 | 1 | 1 | 0 | ||
Head and neck | 2 | 1 | 1 | 2 | ||
Bladder | 2 | 3 | 2 | 3 | ||
Functional Status | ||||||
Adrenergic | 6 | 7 | 0.743 | 1 | 12 | 0.060 |
Noradrenergic | 7 | 5 | 3 | 9 | ||
Silent or Dopaminergic | 7 | 9 | 8 | 8 | ||
Not available | 1 | 3 | 2 | 2 | ||
Metastatic PPGL | ||||||
Yes | 12 | 6 | 0.037 | 9 | 9 | 0.047 |
No | 9 | 18 | 5 | 22 | ||
Ki-67 LI | ||||||
≥3% | 15 | 8 | 0.017 | 13 | 10 | <0.001 |
<3% | 6 | 16 | 1 | 21 | ||
GAPP Score | ||||||
≥7 | 7 | 5 | 0.274 | 5 | 7 | 0.658 |
3–7 | 13 | 14 | 7 | 20 | ||
<3 | 1 | 5 | 2 | 4 | ||
123I-MIBG Uptake | ||||||
Positive | 14 | 19 | 0.226 | 7 | 26 | 0.003 |
Negative | 5 | 2 | 6 | 1 | ||
Not available | 2 | 3 | 1 | 4 | ||
SDHB Staining | ||||||
Positive | 12 | 20 | 0.098 | 4 | 28 | <0.001 |
Negative | 9 | 4 | 10 | 3 |
Abbreviations: SSTR2A, somatostatin receptor 2A; HIF, hypoxia-induced factor; NUC, nuclear; PPGL, pheochromocytoma and paraganglioma; Ki-67 LI, Ki-67 labeling index; MIBG, Metaiodobenzylguanidine; SDHB, succinate dehydrogenase subunit B; GAPP, Grading of Adrenal Pheochromocytoma and Paraganglioma.